Quanterix Appoints Former Illumina CCO Everett Cunningham as CEO with Significant Performance-Based Equity
QTRX sits 64% above its 52-week low of $4.05.
Summary
Quanterix Corporation announced the appointment of Everett Cunningham, former Chief Commercial Officer of Illumina, as its new President and CEO, effective January 19, 2026, alongside a positive preliminary financial outlook for FY2025.
Key Events · Executive and Board Changes · QTRX
-
New CEO Appointed
Everett Cunningham, previously Chief Commercial Officer at Illumina, was appointed President and CEO, effective January 19, 2026. He also joins the Board of Directors.
-
Significant Equity Incentives
Mr. Cunningham received 1,070,000 time-based restricted stock units (RSUs) and 813,750 performance-based RSUs, with vesting tied to stock price targets of $10, $15, and $20 per share.
-
CEO Departure
Masoud Toloue, Ph.D., resigned as President and CEO and from the Board, effective January 19, 2026, receiving severance and accelerated equity vesting.
-
Positive Financial Outlook
The company expects to exceed its revenue and cash guidance for the full fiscal year ended December 31, 2025.
Analysis · QTRX · Industrial Applications And Services
The appointment of Everett Cunningham as CEO is a highly significant development for Quanterix. Mr. Cunningham brings extensive leadership experience from major life sciences and healthcare companies like Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics, and Pfizer, which is a strong positive signal for the company's strategic direction and commercial execution. His compensation package includes substantial performance-based restricted stock units tied to ambitious stock price targets of $10, $15, and $20, strongly aligning his incentives with shareholder value creation. This leadership change, coupled with the company's expectation to exceed its revenue and cash guidance for fiscal year 2025, suggests a renewed focus on growth and operational improvement.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 39.7% of the 353 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QTRX was trading at $6.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $304.1M. The 52-week trading range was $4.05 to $12.21. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.